Replies to post #94189 on Biotech Values

[DewDiligence]

Gammagard [phase-3] trial #1 still enrolling (18 months duration); assume trial #1 to report Jan 2012

Mid 2012 is probably more realistic—see http://www.marketwatch.com/story/baxter-issues-update-on-gammagard-phase-iii-trial-2010-04-14 .

Thanks for your continuing commentary on the AD landscape.